Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

Radiance Biopharma has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical for RB-164 (SYS6005), a novel antibody-drug conjugate targeting ROR115.

The deal covers commercialization rights in the United States, Canada, European Union, United Kingdom, and several other countries15.

Radiance will pay CSPC an upfront payment of $15 million, up to $150 million in potential development and regulatory milestone payments, and over $1 billion in potential commercial milestone payments125.

RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR1, with site-specific conjugation for improved pharmacokinetic and toxicology profiles12.

The drug candidate is currently in a Phase 1 dose escalation clinical trial for advanced liquid and solid tumors in China15.

ROR1 is highly expressed in various hematological malignancies and solid tumors, making it an attractive target for anti-cancer drug development125.

This deal strengthens Radiance's pipeline and positions the company as a significant player in the biopharmaceutical industry15.

The agreement represents a major collaboration between a US-based biotech company and a Chinese pharmaceutical firm in the field of oncology56.

Sources:

1. https://www.biospace.com/press-releases/radiance-biopharma-enters-exclusive-license-for-ror-1-targeted-antibody-drug-conjugate

2. https://ainvest.com/news/radiance-biopharma-enters-exclusive-license-ror-1-targeted-antibody-drug-conjugate-2502-95/

5. https://www.globenewswire.com/news-release/2025/02/19/3029076/0/en/Radiance-Biopharma-Enters-Exclusive-License-For-ROR-1-Targeted-Antibody-Drug-Conjugate.html

6. https://www.fiercebiotech.com/biotech/radiance-rolls-ror1-race-paying-15m-adc-rival-mercks-frontrunner